Madrigal Pharmaceuticals (MDGL) Change in Acquisitions & Divestments (2019 - 2025)
Madrigal Pharmaceuticals (MDGL) has disclosed Change in Acquisitions & Divestments for 12 consecutive years, with $240.1 million as the latest value for Q4 2025.
- Quarterly Change in Acquisitions & Divestments fell 20.59% to $240.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 25.49% year-over-year, with the annual reading at $1.1 billion for FY2025, 25.49% up from the prior year.
- Change in Acquisitions & Divestments for Q4 2025 was $240.1 million at Madrigal Pharmaceuticals, down from $275.1 million in the prior quarter.
- The five-year high for Change in Acquisitions & Divestments was $302.4 million in Q4 2024, with the low at $12.0 million in Q1 2023.
- Average Change in Acquisitions & Divestments over 5 years is $151.0 million, with a median of $116.6 million recorded in 2023.
- The sharpest move saw Change in Acquisitions & Divestments crashed 87.18% in 2023, then surged 1422.61% in 2024.
- Over 5 years, Change in Acquisitions & Divestments stood at $70.5 million in 2021, then grew by 12.33% to $79.2 million in 2022, then surged by 43.69% to $113.8 million in 2023, then surged by 165.75% to $302.4 million in 2024, then fell by 20.59% to $240.1 million in 2025.
- According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $240.1 million, $275.1 million, and $273.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.